Trek Therapeutics Acquires Two Antiviral Inhibitors From Vertex Pharmaceuticals

Trek Therapeutics Acquires Two Antiviral Inhibitors From Vertex Pharmaceuticals


Trek Therapeutics, a private, clinical stage public benefit corporation developing affordable and accessible treatment regimens for chronic hepatitis C virus infection today announced that it acquired the worldwide development and commercialization rights to treat infectious disease with lomibuvir , a non-nucleoside inhibitor of the HCV NS5B polymerase and merimepodib , an inhibitor of inosine monosphosphate dehydrogenase with broad-spectrum antiviral properties from Vertex Pharmaceuticals Incorporated. Vertex will be eligible to receive milestones and royalties based on successful development and commercialization of lomibuvir and merimepodib.



from Biotech News